4CPS-069 Economic impact of off-label use of dalbavancin for treatment of infectious endocarditis and bloodstream infections caused by grampositive bacteria

BACKGROUND: Dalbavancin (DBV) is an antibiotic from the lipoglycopeptide family that is active against Gram +cocci (GPC) that reaches adequate concentrations to allow dosing once a week. It is currently only approved for skin and soft tissue infections, although its PK/PD properties could allow a po...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Hosp Pharm
Autori principali: de Jesús, S, Sadyrbaeva, S, Hidalgo-Tenorio, C, Jiménez-Morales, A, Pasquau, J
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Group 2018
Soggetti:
Section 4: Clinical pharmacy services
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535182/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.160
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi